Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aneil Mujoomdar"'
Autor:
Lujain Attar, MD, Daniel French, MD, Daria Manos, MD, Nicholas Finn, MD, Aneil Mujoomdar, MD, Alison Wallace, MD, PhD
Publikováno v:
Annals of Thoracic Surgery Short Reports, Vol 2, Iss 3, Pp 492-494 (2024)
Osteosarcoma, the most common primary bone tumor in young individuals, frequently metastasizes hematogenously to the lungs, necessitating pulmonary metastasectomy as a common surgical procedure. While sublobar and lobar resections are accepted approa
Externí odkaz:
https://doaj.org/article/7425882dac4342dcbc20f898e3ad2e60
Autor:
Gopal P. Pathak, Rashmi Shah, Mathieu Castonguay, Angela Cheng, John Fris, Rowan Murphy, Gail Darling, Alexander Ednie, Daniel French, Harry Henteleff, Aneil Mujoomdar, Madelaine Plourde, Alison Wallace, Zhaolin Xu
Publikováno v:
Cancer Medicine, Vol 13, Iss 19, Pp n/a-n/a (2024)
ABSTRACT Objectives Several studies rely on archived tissue blocks to assess the PD‐L1 scores; however, a detailed analysis of potential variations of scores between fresh and archived tissue blocks still lacks. In addition, the prognostic implicat
Externí odkaz:
https://doaj.org/article/ff5a5695ce2448108b9d6431f5d82b1b
Autor:
Ahmed Jad, Drew Bethune, Aneil Mujoomdar, Daniel French, Harry Henteleff, Kyla Harris, Patrick Dorn, Madelaine Plourde
Publikováno v:
The Annals of Thoracic Surgery. 106:1628-1632
Background Digital chest drainage devices objectively measure airflow to guide chest tube management. There are contradictory results regarding their utility in reducing length of stay and chest tube duration. The objective of this study was to compa
Air leaks are the most common complication after pulmonary resection. Enhanced recovery after surgery (ERAS) programs must be designed to manage parenchymal air leaks. ERAS programs should consider two components when creating protocols for air leaks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab12af254fc556e04133d66b3122090e
https://europepmc.org/articles/PMC6258660/
https://europepmc.org/articles/PMC6258660/
Autor:
Wenda L. Greer, Micheal Johnston, Zhaolin Xu, Harry Henteleff, Daniel French, Paola Marcato, Aneil Mujoomdar, Marika Forsythe, Mathieu Castonguay, Gorden Flowerdew, Madelaine Plourde, Akram Alwithenani, Drew Bethune
Publikováno v:
Clinical Cancer Research. 24:B21-B21
Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options to chemotherapies that have very low response rate. New therapies that target driver gene mutations (e.g., EGFR, ALK, ROS1, BRAF) are being used to treat p